原发性肝癌并门静脉癌栓的肝动脉化疗栓塞治疗  

Trans-arterial chemotherapy and embolization for the treatment of primary hepatic carcinoma complicated with portal vein tumor thrombus

作　　者：李凯滨[1] 黄肇云[1] 罗剑云[1] 陈亚炎[1] 

机构地区：[1]肇庆市第一人民医院肿瘤科,广东省526021

出　　处：《中华普通外科杂志》2005年第12期768-770,共3页Chinese Journal of General Surgery

摘　　要：目的评价经肝动脉化疗栓塞术治疗原发性肝癌并门静脉癌栓的疗效和安全性。方法原发性肝癌并门静脉癌栓患者83例,其中53例行肝动脉化疗栓塞术(栓塞组),30例行肝动脉化学药物灌注(对照组)。对两组的疗效和并发症进行比较。结果经介入治疗后,栓塞组患者 6、12、24、36个月的生存率分别为97．8％、85．2％、45．8％、4．4％,均高于对照组(37．6％、5．3％、0、0． P均<0．01)。两组患者术后并发症的发生率差异无统计学意义。结论原发性肝癌并门静脉癌栓行经肝动脉化疗栓塞术较化疗灌注术的疗效好。Objective To evaluate the effect and safety of trans-arterial chemotherapy embolization （TACE） in the treatment of primary hepatic carcinoma （PHC）with portal vein tumor thrombus. Methods There were 83 PHC patients complicated with portal vein tumor thrombus, age ranging from 29 to 76 years. Fifty-three cases underwent TACE （ Group A） ,30 receiving trans-arterial chemotherapy infusion only （TAI, Group B）. Results The survival rate in group A at 6,12,24 and 36 months was 97.8% , 85.2% , 45.8% and 4.4% , respectively, significantly higher than that in group B （37.6% ,5.3% ,0,0, P 〈0.01 ）. Complication rate was similar between the two groups. Conclusion TACE is more effective than TAI for the treatment of PHC with portal vein tumor thrombus.

关 键 词：癌 肝细胞 门静脉 癌栓 放射学 介入治疗性 

分 类 号：R735.7[医药卫生—肿瘤] R551.305[医药卫生—临床医学]